February 7-11, 2026
Thomas Michael Menino Convention & Exhibition Center (MCEC)
Boston, MA, USA
February 7-11, 2026
Thomas Michael Menino Convention & Exhibition Center (MCEC)
Boston, MA, USA
Serena Silver, Ph.D., is the Chief Scientific Officer at Accent Therapeutics (Lexington, MA, USA), a clinical-stage biotechnology company that aims to translate extraordinary science into life-changing therapeutics for patients living with cancer. Prior to joining Accent, Serena served as Vice President of Discovery Biology and Technologies at Fulcrum Therapeutics, where she led scientific teams to develop and deploy new assay modalities and complex cellular models of disease to identify targets and discover therapeutics for rare diseases. Previously, Serena led the Molecular Pharmacology group at Novartis Oncology, the Target ID & Validation team at Sanofi Oncology, and worked at the forefront of functional genomics screening technology at the Broad Institute. Dr. Silver earned a Ph.D. in Biology from the Massachusetts Institute of Technology and completed a postdoctoral fellowship at Harvard Medical School.
Director, Friedman Brain Institute
Chair, Nash Family Department of Neuroscience, Icahn School of Medicine, Mount Sinai
Paul J. Kenny, Ph.D., is Ward-Coleman Professor and Chair of the Nash Family Department of Neuroscience; he also serves as the Director of the Drug Discovery Institute and Director of the NIDA T32 Training Program in Substance Use Disorders at the Icahn School of Medicine at Mount Sinai. Kenny’s multidisciplinary research defines molecular and circuit mechanisms of addiction, pain, obesity, and schizophrenia, integrating transcriptomic, genetic and behavioral approaches.
Kenny earned his undergraduate degree in biochemistry from Trinity College Dublin and a PhD in neuropsychopharmacology from King’s College London. Following postdoctoral training at The Scripps Research Institute, he joined the Scripps faculty in 2006, rising to tenured Associate Professor before being recruited to Mount Sinai in 2013. Kenny also co-founded Eolas Therapeutics, advancing NIH-funded orexin-1 receptor antagonists through Phase 1 trials. Eolas is now preparing for Phase 2 human clinical trials for substance use disorders. Dr. Kenny’s work has earned numerous honors, including the Jacob P Waletzky Memorial Award from the Society for Neuroscience), Daniel H. Efron Award from the American College of Neuropsychopharmacology, and the 2025 Jacobi Medallion.